Disease · MONDO_0004986
Comparisons in its trials18
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 18 of 18
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Durvalumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin: Proportion of Patients Who Undergo Cystectomy | 469 of 533 | 441 of 530 | 1,063 | NCT03732677 | Trial comparisons |
| Durvalumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin: Pathologic Complete Response (pCR) Rates at Time of Cystectomy | 199 of 533 | 146 of 530 | 1,063 | NCT03732677 | Trial comparisons |
| Durvalumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin: deaths from any cause | 27 of 533 | 29 of 526 | 1,059 | NCT03732677 | Trial comparisons |
| Durvalumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin: serious adverse events | 326 of 530 | 287 of 526 | 1,056 | NCT03732677 | Trial comparisons |
| Enfortumab Vedotin - Cohort 1 vs Enfortumab Vedotin - Cohort 2: deaths from any cause | 104 of 125 | 72 of 89 | 214 | NCT03219333 | Trial comparisons |
| Enfortumab Vedotin - Cohort 1 vs Enfortumab Vedotin - Cohort 2: serious adverse events | 59 of 125 | 35 of 89 | 214 | NCT03219333 | Trial comparisons |
| HER2+ :RT, Paclitaxel, and Trastuzumab vs HER2- :RT and Paclitaxel: Acute Treatment-related Toxicity | 7 of 21 | 14 of 47 | 68 | NCT00238420 | Trial comparisons |
| HER2+ :RT, Paclitaxel, and Trastuzumab vs HER2- :RT and Paclitaxel: Treatment Completion | 13 of 21 | 34 of 47 | 68 | NCT00238420 | Trial comparisons |
| HER2+ :RT, Paclitaxel, and Trastuzumab vs HER2- :RT and Paclitaxel: serious adverse events | 6 of 21 | 15 of 47 | 68 | NCT00238420 | Trial comparisons |
| Group I (Erlotinib Hydrochloride) vs Group II (Placebo): deaths from any cause | 0 of 24 | 0 of 13 | 37 | NCT02169284 | Trial comparisons |
| Group I (Erlotinib Hydrochloride) vs Group II (Placebo): serious adverse events | 1 of 24 | 2 of 13 | 37 | NCT02169284 | Trial comparisons |
| Arm Ib: Safety Run In Phase Ib vs Arm II: Investigational Treatment Phase II: deaths from any cause | 4 of 6 | 8 of 20 | 26 | NCT02891161 | Trial comparisons |
| Arm Ib: Safety Run In Phase Ib vs Arm II: Investigational Treatment Phase II: serious adverse events | 4 of 6 | 8 of 20 | 26 | NCT02891161 | Trial comparisons |
| Cohort I (Durvalumab, DD MVAC) vs Cohort III (Durvalumab, Carbo-gem): deaths from any cause | 0 of 3 | 0 of 3 | 6 | NCT03912818 | Trial comparisons |
| Cohort I (Durvalumab, DD MVAC) vs Cohort III (Durvalumab, Carbo-gem): serious adverse events | 2 of 3 | 3 of 3 | 6 | NCT03912818 | Trial comparisons |
Cohort I (Durvalumab, DD MVAC) vs Cohort III (Durvalumab, Carbo-gem): Proportion of Subjects Who Initiate Study Treatment and Achieve Tumor Stage of pT2 N0 M0 or Better (e.g., pT0, pT1 N0) at Cystectomy | 1 of 3 | 1 of 2 | 5 | NCT03912818 | Trial comparisons |
| Gemcitabine + Carboplatin + Avelumab + Surgery vs Surgery Only: deaths from any cause | 0 of 2 | 1 of 1 | 3 | NCT04871529 | Trial comparisons |
| Gemcitabine + Carboplatin + Avelumab + Surgery vs Surgery Only: serious adverse events | 0 of 2 | 0 of 1 | 3 | NCT04871529 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004986/comparisons